Artificial Intelligence-Powered Human Epidermal Growth Factor Receptor 2 and Tumor Microenvironment Analysis in Human Epidermal Growth Factor Receptor 2-Amplified Metastatic Colorectal Cancer: Exploratory Analysis of Phase II TRIUMPH Trial.

Journal: JCO precision oncology
PMID:

Abstract

PURPOSE: Human epidermal growth factor receptor 2 (HER2)-targeted therapies have shown promise in treating -amplified metastatic colorectal cancer (mCRC). Identifying optimal biomarkers for treatment decisions remains challenging. This study explores the potential of artificial intelligence (AI) in predicting treatment responses to trastuzumab plus pertuzumab (TP) in patients with -amplified mCRC from the phase II TRIUMPH trial.

Authors

  • Mitsuho Imai
    Translational Research Support Office, Division of Drug and Diagnostic Development Promotion, Department for the Promotion of Drug and Diagnostic Development, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
  • Yoshiaki Nakamura
    Translational Research Support Office, National Cancer Center Hospital East, Chiba, Japan.
  • Sangwon Shin
    Lunit, Seoul, Republic of Korea.
  • Wataru Okamoto
    Department of Clinical Oncology, Hiroshima University Hospital, Hiroshima, Japan.
  • Takeshi Kato
  • Taito Esaki
    Department of Gastrointestinal and Medical Oncology, NHO Kyushu Cancer Center, Fukuoka, Japan.
  • Ken Kato
    Acute Cardiac Care, Andreas Grüntzig Heart Catheterization Laboratories, Department of Cardiology, University Heart Center, University Hospital Zurich, University of Zurich, Raemistrasse 100, 8091, Zurich, Switzerland.
  • Yoshito Komatsu
    Department of Cancer Center, Hokkaido University Hospital, Hokkaido, Japan.
  • Satoshi Yuki
    Department of Gastroenterology and Hepatology, Hokkaido University Hospital, Hokkaido, Japan.
  • Toshiki Masuishi
    Department of Clinical Oncology, Aichi Cancer Center, Nagoya, Japan.
  • Tomohiro Nishina
    Gastrointestinal Medical Oncology, NHO Shikoku Cancer Center, Ehime, Japan.
  • Kentaro Sawada
    Department of Medical Oncology, Kushiro Rosai Hospital, Kushiro, Japan.
  • Akihiro Sato
    Clinical Research Support Office, National Cancer Center Hospital East, Chiba, Japan.
  • Takeshi Kuwata
    Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
  • Riu Yamashita
    Department of Integrative Genomics, Tohoku Medical Megabank Organization, Tohoku University, 2-1, Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8573, Japan.
  • Takao Fujisawa
    Translational Research Support Office, Division of Drug and Diagnostic Development Promotion, Department for the Promotion of Drug and Diagnostic Development, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
  • Hideaki Bando
    Translational Research Support Office, Division of Drug and Diagnostic Development Promotion, Department for the Promotion of Drug and Diagnostic Development, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
  • Chan-Young Ock
    Lunit, Seoul, Korea (the Republic of) jeannes@stanford.edu ock.chanyoung@lunit.io.
  • Satoshi Fujii
    Division of Pathology, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center East, Kashiwa, Chiba, Japan.
  • Takayuki Yoshino
    National Cancer Center Hospital East, Chiba, Japan.